Results 41 to 50 of about 229,521 (146)
ABSTRACT Background Thyroid‐associated ophthalmopathy (TAO) may lead to severe exophthalmos and dysthyroid optic neuropathy (DON), which can threaten visual function. Orbital decompression surgery is often required when medical therapy is insufficient; however, traditional deep lateral wall decompression techniques remain associated with several ...
Shuo Wu +4 more
wiley +1 more source
Improvement Of Graves' Ophthalmopathy After Administration Of The Cyclooxygenase-2 Selective Inhibitor Celecoxib: A Case-Report [PDF]
Graves' ophthalmopathy (GO) is a disabling complication of GravesBasedow disease, which in severe cases can progress toward blindness. Its treatment consists of the administration of corticosteroids, radiotherapy, as well as surgical treatment.
Roman, Deiana +4 more
core +1 more source
Oxidative stress induces endothelial nitric oxide synthase (eNOS) uncoupling and L‐arginine depletion, reducing nitric oxide (NO) bioavailability in vascular endothelium and contributing to decreased retinal capillary density (RCD) in dysthyroid optic neuropathy (DON).
Yunhai Tu +12 more
wiley +1 more source
Background Ocular myasthenia gravis and Graves’ ophthalmopathy are autoimmune diseases that are mediated by membrane receptors and share many identical clinical processes.
Jingqun Tang, Chao Qin
doaj +1 more source
Graves Ophthalmopathy: A Review of Immunogenetics [PDF]
Graves' disease (GD) is the most common cause of thyrotoxicosis and often involves the orbits. Graves' ophthalmopathy (GO), also known as Thyroid Eye Disease (TED), can be clinically significant and advance to sight-threatening stages. Our knowledge of the immunogenetic pathophysiology of GO is rapidly expanding.
Khalilzadeh, Omid +3 more
openaire +2 more sources
The diagnostic model combining orbital and intracranial MAP‐MRI parameters could significantly optimize diagnostic efficiency of dysthyroid optic neuropathy. Comprehensive MAP‐MRI parameters analysis of the entire visual pathway enables a deeper understanding of disease involvement, provides novel insights into the early accurate diagnosis and ...
Mengsha Zou +7 more
wiley +1 more source
Treatment of Graves' ophthalmopathy with Cyclosporin A [PDF]
To evaluate the effect of Cyclosporin A in the management of Graves' ophthalmopathy, we treated 13 patients with severe euthyroid endocrine eye disease with the immunosuppressive drug. Follow up consisted of clinical investigation, laboratory evaluation with detailed thyroid function tests and complete ophthalmological assessments including A and B ...
A, Witte +5 more
openaire +2 more sources
Teprotumumab for Thyroid Eye Disease: Efficacy and Impact on Orbital Decompression Utilization
Teprotumumab has been proven effective in thyroid eye disease and associated exophthalmos management. Since its FDA approval in 2020, teprotumumab therapy has been a popular choice for managing exophthalmos which has resulted in decreased utilization of orbital decompression surgery, from 36.8% between 2015 and 2020 to 11.1% TED patients between 2020 ...
Nitish Kumar +5 more
wiley +1 more source
Clinical and Radiological Findings in Patients with Newly Diagnosed Graves’ Ophthalmopathy
Background. Graves’ ophthalmopathy is the most common extrathyroidal manifestation of Graves’ disease. The objective of this study was to investigate the clinical ophthalmological and MRI findings in newly diagnosed Graves’ ophthalmopathy. Methods.
Yakup Cevik +4 more
doaj +1 more source
Graves’ ophthalmopathy (GO), also known as thyroid-associated ophthalmopathy, is a common potentially vision-threatening organ-specific autoimmune disease and the most common extrathyroidal manifestation of Graves’ disease.
Jingyi Zheng +8 more
doaj +1 more source

